Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults, marked by high treatment resistance and poor prognosis. OLIG2, a CNS-specific transcription factor essential for neural development, is highly expressed in GBM and contributes to tumor progression and therapy resistance, making it a promising target for novel therapeutic strategies.